A BIFUNCTIONAL TUMOR ACTIVATED IMMUNOMODULATOR (TRACIR) TARGETING PD-L1 AND CD28 IS A POTENT ENHANCER OF T CELL-MEDIATED ANTI-TUMOR ACTIVITY

被引：0

作者：

DiRaimondo, Thomas ^{[1
]}

Budimir, Natalija ^{[1
]}

Ma, Lina ^{[1
]}

Shenhav, Simon ^{[1
]}

Cicchini, Vanessa ^{[1
]}

Navert, Robert ^{[1
]}

Wu, Hua ^{[1
]}

Jocic, Renee ^{[1
]}

Yu, Cuiling ^{[1
]}

Aceveda, Diane ^{[1
]}

Best, Hannah ^{[1
]}

Prentiss, Clara ^{[1
]}

Muskat, Kai ^{[1
]}

Chang, Jason ^{[1
]}

Dastmalchi, Farhad ^{[1
]}

Roup, Fabrece ^{[1
]}

Caffaro, Carolina ^{[1
]}

Aerni, Hans ^{[1
]}

Godfrey, Wayne ^{[1
]}

Winter, Charles ^{[1
]}

Nasoff, Marc ^{[1
]}

Gibson, Neil ^{[1
]}

Campbell, David ^{[1
]}

Salek-Ardakan, Shahram ^{[1
]}

机构：

[1] Janux Therapeut, San Diego, CA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.1326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1326

引用

页码：A1377 / A1377

页数：1

共 50 条

[31] HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression
Li, Xiaolei
Su, Xiao
Liu, Rui
Pan, Yongsha
Fang, Jiankai
Cao, Lijuan
Feng, Chao
Shang, Qianwen
Chen, Yongjing
Shao, Changshun
Shi, Yufang
ONCOGENE, 2021, 40 (10) : 1836 - 1850
[32] Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models
Mahdi, Haider S.
Woodall-Jappe, Mary
Singh, Preeti
Czuczman, Myron S.
FRONTIERS IN IMMUNOLOGY, 2023, 14
[33] Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment
Li, Jie
Cao, Peiyu
Chen, Yuxin
Wang, Junqi
Sun, Xiaolei
Chen, Renfu
Wang, Gang
Hou, Jianquan
EXPERIMENTAL CELL RESEARCH, 2022, 417 (01)
[34] Sharks give a handle to potent anti-tumor multiparatopic antibodies inducing membrane depletion of PD-L1
Wozniak-Knopp, Gordana
Natale, Veronica
CELL CHEMICAL BIOLOGY, 2024, 31 (05) : 833 - 834
[35] Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, Suzanne L.
Drake, Charles G.
Pardoll, Drew M.
CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) : 207 - 212
[36] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
Albu, Diana I.
Wolf, Benjamin J.
Qin, Yan
Wang, Xianzhe
Ulumben, Amy Daniel
Su, Mei
Li, Vivian
Ding, Eirene
Gonzalo, Jose Angel
Kong, Jason
Jadhav, Ruturaj
Kuklin, Nelly
Visintin, Alberto
Gong, Bing
Schuetz, Thomas J.
ONCOIMMUNOLOGY, 2024, 13 (01):
[37] Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells
Christo, Susan N.
Mcdonald, Keely M.
Burn, Thomas N.
Kurd, Nadia
Stanfield, Jessica
Kaneda, Megan M.
Seelige, Ruth
Dillon, Christopher P.
Fisher, Timothy S.
Baaten, Bas
Mackay, Laura K.
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (11)
[38] D-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity
Dong, Wenjing
Lin, Mingen
Zhang, Ruonan
Sun, Xue
Li, Hongchen
Liu, Tianshu
Xu, Yanping
Lv, Lei
CANCER LETTERS, 2024, 591
[39] A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice
Pan, Jiayi
Zeng, Wuyi
Jia, Jiangtao
Shi, Yi
Wang, Danni
Dong, Jun
Fang, Zixuan
He, Jiashan
Yang, Xinyu
Zhang, Rong
He, Menghua
Huang, Maoping
Fu, Bishi
Zhong, Bei
Liu, Hui
VACCINES, 2022, 10 (07)
[40] SM2275, A tetraspecific, dual EGFR and PD-L1-targeting, conditionally activating co-stimulatory CD28 and simultaneously blocking PD-1/PD-L1 signaling to promoting fully activated T cell killing effects on tumor cells
Lu, Shihao
Liu, Xiaodan
Zhou, Sheila
Song, Wenjing
Geng, Huiqin
Yang, Simin
Zhou, Hong
Xie, Siyao
Wei, Yi
Zhang, Xing
Liang, Yanbin
CANCER RESEARCH, 2024, 84 (06)

← 1 2 3 4 5 →